UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
___________________
 
FORM 8-K
___________________
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported): November 15, 2016
___________________
 
FLAMEL TECHNOLOGIES S.A.
(Exact name of registrant as specified in its charter)
___________________
 
Republic of France  
(State or Other Jurisdiction  
of Incorporation)
 
 
000-28508  
(Commission File Number)
98-0639540
(I.R.S. Employer  
Identification No.)
 
Parc Club du Moulin à Vent  
33, avenue du Docteur Georges Levy  
69200 Vénissieux France
(Address of Principal Executive Offices)
 
 
 
Not Applicable
(Zip Code)
 
 
 
Registrant's telephone number, including area code: 011 +33 472 78 34 34
___________________
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
£  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
£  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
£  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
£  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 



 
Item 7.01   Other Events.
 
On November 16, 2016, Flamel Technologies S.A. (the “Company”) intends to make a presentation at Jefferies 2016 Healthcare Conference in London, England. A copy of the Company’s complete slide presentation to be used at the Conference is being furnished as Exhibit 99.1 to this Current Report on Form 8-K. The Company’s presentation will be webcast live and can be accessed by visiting the Investor section of the Company’s website at http://www.flamel.com/investors. A replay of the presentation, together with the complete slide presentation, will also be available and archived for at least 30 days on the website following the event.
 
The information responsive to Item 7.01 of this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as may be expressly set forth by specific reference in such a filing. 

Item 9.01   Financial Statements and Exhibits.
 
(d) Exhibits
 
99.1
 
Form of Slide Presentation of Flamel Technologies   S.A. as of November 15, 2016.
 
 
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
FLAMEL TECHNOLOGIES S.A.
By:  /s/ Phillandas T. Thompson
Phillandas T. Thompson
Senior Vice President, General Counsel and Corporate Secretary
Date: November 15, 2016
 
Exhibit Index
 
 
99.1
 
Form of Slide Presentation of Flamel Technologies S.A. as of November 15, 2016.
 
 

Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Avadel Pharmaceuticals Charts.
Avadel Pharmaceuticals (NASDAQ:AVDL)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Avadel Pharmaceuticals Charts.